MX2022005440A - Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2). - Google Patents

Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).

Info

Publication number
MX2022005440A
MX2022005440A MX2022005440A MX2022005440A MX2022005440A MX 2022005440 A MX2022005440 A MX 2022005440A MX 2022005440 A MX2022005440 A MX 2022005440A MX 2022005440 A MX2022005440 A MX 2022005440A MX 2022005440 A MX2022005440 A MX 2022005440A
Authority
MX
Mexico
Prior art keywords
mmp2
polypeptide
inhibitory effect
effect
represented
Prior art date
Application number
MX2022005440A
Other languages
English (en)
Inventor
Rie Shimono
Masato Hayashi
Tomoki Takeuchi
Yusaku Nomura
Tomoko Tamita
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2022005440A publication Critical patent/MX2022005440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un polipéptido sustituido o una sal farmacéuticamente aceptable del mismo con efecto inhibidor de MMP2, el polipéptido sustituido representado por la fórmula [I']: (ver Fórmula).
MX2022005440A 2019-11-08 2020-11-06 Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2). MX2022005440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019203338 2019-11-08
PCT/JP2020/042350 WO2021090959A1 (ja) 2019-11-08 2020-11-06 Ｍｍｐ２阻害作用を有するポリペプチド

Publications (1)

Publication Number Publication Date
MX2022005440A true MX2022005440A (es) 2022-05-30

Family

ID=75849183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005440A MX2022005440A (es) 2019-11-08 2020-11-06 Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).

Country Status (12)

Country Link
EP (1) EP4056581A4 (es)
JP (1) JPWO2021090959A1 (es)
KR (1) KR20220093087A (es)
CN (1) CN114450294A (es)
AU (1) AU2020380902A1 (es)
BR (1) BR112022007729A2 (es)
CA (1) CA3160310A1 (es)
IL (1) IL292684A (es)
MX (1) MX2022005440A (es)
TW (1) TW202132327A (es)
WO (1) WO2021090959A1 (es)
ZA (1) ZA202205158B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406565A (zh) * 2022-04-18 2024-02-16 日商大正製藥股份有限公司 含有具有ｍｍｐ２抑制作用之化合物作為有效成分之肺之炎症及纖維症之預防或治療藥

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
KR101363455B1 (ko) * 2011-09-09 2014-02-21 (주)케어젠 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
KR101744959B1 (ko) * 2014-12-05 2017-06-12 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
EP4056581A1 (en) 2022-09-14
ZA202205158B (en) 2023-11-29
JPWO2021090959A1 (es) 2021-05-14
IL292684A (en) 2022-07-01
AU2020380902A1 (en) 2022-05-26
TW202132327A (zh) 2021-09-01
CN114450294A (zh) 2022-05-06
BR112022007729A2 (pt) 2022-07-12
KR20220093087A (ko) 2022-07-05
EP4056581A4 (en) 2023-11-29
CA3160310A1 (en) 2021-05-14
WO2021090959A1 (ja) 2021-05-14

Similar Documents

Publication Publication Date Title
ZA202208783B (en) Kras mutant protein inhibitors
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2021009854A (es) Compuesto derivado heterociclico novedoso y uso del mismo.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2021014680A (es) Derivado de benzotriazol.
MX2021012105A (es) Compuestos de pirrol.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MY193239A (en) Novel b-lactamase inhibitors
ZA202204442B (en) Salt forms of a complement component c5a receptor
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.